Compare JGH & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JGH | ENTA |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.2M | 382.7M |
| IPO Year | N/A | 2012 |
| Metric | JGH | ENTA |
|---|---|---|
| Price | $12.62 | $15.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 88.4K | ★ 230.9K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | N/A | $7.76 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $11.80 | $6.44 |
| 52 Week High | $13.70 | $17.15 |
| Indicator | JGH | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 67.66 |
| Support Level | $12.40 | $13.19 |
| Resistance Level | $12.92 | $15.48 |
| Average True Range (ATR) | 0.20 | 0.78 |
| MACD | -0.02 | 0.33 |
| Stochastic Oscillator | 43.10 | 89.77 |
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The Fund's securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.